Fujian Cancer Hospital clinical trials
Listed in the registry as: Government agency.
The registry lists 162 studies whose lead sponsor is Fujian Cancer Hospital. 92 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Fujian Cancer Hospital studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- China
- 98
Focus areas
Conditions Fujian Cancer Hospital leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 162. Browse all 162 →
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCRecruitingNCT07331428Phase 2
- Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast CancerRecruitingNCT07880600
- PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLMRecruitingNCT06788171Phase 2
- SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingNCT07470840Phase 2
- Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal CancerRecruitingNCT07469306Phase 2
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2
- Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLCEnrolling by invitationNCT07738367Phase 2
- Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast CancerRecruitingNCT07702708
- Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast CancerNot yet recruitingNCT07691333Phase 2
- A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical CancerNot yet recruitingNCT07613567Phase 3
- A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With BiomarkersNot yet recruitingNCT07613905Not applicable
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingNCT07581834Phase 2
- SKB264 Plus QL1706 in Recurrent or Metastatic Cervical CancerRecruitingNCT07256236Phase 2
- Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine CreamNot yet recruitingNCT07492654Phase 4
- Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentRecruitingNCT07467330Phase 3
- SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver MetastasesRecruitingNCT06787183Phase 2
- CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction ChemotherapyNot yet recruitingNCT07399158
- Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07388836Phase 2
- Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)RecruitingNCT07320105Phase 4
- Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune IntoleranceNot yet recruitingNCT07313202Phase 2
- Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase IINot yet recruitingNCT07310771Phase 2
- The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver CancerNot yet recruitingNCT07306481Not applicable
- Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal CarcinomaNot yet recruitingNCT07268690Phase 3
- A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal CarcinomaNot yet recruitingNCT07252375Phase 2
- Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 StudyNot yet recruitingNCT07243418Phase 2
- Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the EsophagealNot yet recruitingNCT07155122Phase 2
- Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)RecruitingNCT07055399Phase 2
- Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical TrialRecruitingNCT07142122Not applicable
- Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNot yet recruitingNCT07101159Phase 2
- Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingNCT07088484
- Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06793917Phase 3
- Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or SurgeryNot yet recruitingNCT07046221Phase 2
- Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingNCT07070713Phase 2
- A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and ChemotherapyNot yet recruitingNCT07069270Phase 2
- SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06979986Not applicable
- CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal CarcinomaRecruitingNCT06095154Phase 3
- Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06692270Phase 2
- Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingNCT05319639Phase 1/2
- A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung CancerNot yet recruitingNCT06786312Phase 2
- Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal CancerNot yet recruitingNCT06775756Phase 3
- A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.Not yet recruitingNCT06746545Phase 2
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
- Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal CarcinomaNot yet recruitingNCT06572293Not applicable
- A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung CancerNot yet recruitingNCT06614621Phase 2
- Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical CancerRecruitingNCT06140589
- Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian CancerNot yet recruitingNCT06600841Phase 2
- Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerRecruitingNCT05019690Phase 1/2
- Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal CancerNot yet recruitingNCT05628610Phase 2
- SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular CarcinomaNot yet recruitingNCT06538935Phase 2
- Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative GenesNot yet recruitingNCT06490913Phase 2